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Background & Objective: Previous studies have addressed the electrolyte 
abnormalities such as hypocalcemia in COVID-19 patients. We aimed to compare the 
laboratory findings especially the electrolyte levels among COVID-19 patients and 
healthy controls and evaluate their prognostic values. 
Methods: This case-control study included 91 COVID-19 patients and 169 healthy 
individuals. Their laboratory parameters including electrolytes, albumin, liver enzymes, 
complete blood count, vitamin D, and parathyroid hormone (PTH) were compared. We 
also analyzed the association between these markers and the major outcomes including 
severity, mortality and hospitalization. 
Results: Among patients with COVID-19, 59.3% of the patients had hypocalcemia 
on admission while in control group only 32.5% had low calcium level (OR=3.02, 95% 
CI: 1.79-5.13, P<0.001). The rates of death and ICU admission were significantly 
higher among the patients in hypocalcemic group than those of eucalcemic group 
(85.7% vs 14.3% and 33.3% Vs 9.1%, respectively). However, there was no significant 
difference in the mean PTH and vitamin D levels between the two groups. In terms of 
the severity of the infection, 74.1% of patients in hypocalcemic group had a severe 
infection while 24.3% of the patients in eucalcemic group were diagnosed with severe 
infection (OR=8.89, 95% CI: 3.38-23.37, P<0.001). 
Conclusion: Patients with COVID-19 may present with considerable laboratory 
abnormalities including hypocalcemia. The hypocalcemia would be also associated 
with worse major clinical outcome and higher mortality risk. 
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Introduction
Pneumonia caused by COVID-19 infection is an 
emerging infectious disorder that has gained a 
worldwide public health attention (1). The world health 
organization (WHO) has issued diagnostic strategies and 
treatment recommendations and suggested classifying 
COVID-19 disease into 4 stages: mild, moderate, severe 
and critical (2). Recent studies have reported the clinical 
characteristics and outcomes of COVID-19 with 
different severity (3-5). The underlying mechanisms of 
the novel coronavirus leading to disease progression and 
organs dysfunction remain to be explored. Due to the 
high mortality and the lack of effective treatments in 
critical patients (6-8), early identification of these 
patients is crucial. If we know the risk factors for 
progression of the patients to severe or critical stages of 
COVID-19, we can identify the groups with most likely 
poor outcomes, so that, we can focus on prevention and 
treatment efforts. Recent studies have reported that 
patients admitted into the intensive care unit (ICU) had 
more abnormal serum parameters (7). While 
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lymphopenia, elevated lactate dehydrogenase, liver 
enzymes, creatinine kinase (CK) and C-reactive protein 
(CRP) are among the most common laboratory findings 
of COVID-19 patients, other laboratory parameters such 
as electrolyte imbalances are also increasingly have been 
recognized as important factor among COVID-19 
patients (4,6,7). The electrolyte imbalance, especially 
hypocalcemia, plays an important role in the patients' 
health management (1), and may be involved in the 
pathophysiologic mechanisms dictated by this viral 
agent. We observed a high incidence of hypocalcemia in 
the COVID-19 patients with severe disease. Therefore, 
we hypothesized that serum calcium levels were 
associated with the disease severity and prognosis of 
patients with COVID-19 infection.  
Accordingly, we designed a case-control study to 
investigate the electrolyte imbalances; especially 
hypocalcemia, in the patients affected by COVID-19, 
and compared findings to a matched control group with 
no COVID-19 infection. Also, we aimed to investigate 
the association between the level of calcium and major 
clinical outcomes including mortality, ICU admission 
and duration of hospitalization in the COVID-19 
patients. 
Materials and Methods 
Patients and Controls 
This case-control study was carried out on adults ≥18 
years of age who referred to Hajar Hospital, Shahrekord 
University of Medical Science, Shahrekord, Iran, with 
COVID-19 infection from February to April 2020 with 
their matched healthy controls. The clinical outcomes 
such as mortality, organ injury, and discharges were 
monitored until the time of their discharge or death until   
April 26, 2020.  
Our cases included the patients with definitive 
COVID-19 disease confirmed by a positive real-time 
reverse transcriptase-polymerase chain reaction (RT-
PCR) assay on the nasopharyngeal swab specimens (9). 
Hypocalcemia was defined as a serum calcium level less 
than 8.6 mg/dL. 
The severity of the COVID-19 infection was 
classified based on the WHO-China joint mission. Mild: 
minor clinical symptoms (e.g., fever and cough) with no 
manifestations on imaging; Moderate: fever, or 
respiratory tract infection symptoms with imaging 
indicating pneumonia; Severe: meet at least one of the 
following criteria: respiratory rate≥30 breaths/min, 
oxygen saturation (SpO2)≤93%, lung infiltration >50% 
of the lungs on imaging, and require ICU admission (2). 
A control group of 169 healthy adults were selected 
using the data registry of a reference laboratory in the 
same city. The age, sex and laboratory findings 
(including electrolytes, albumin, liver enzymes, 
complete blood count, vitamin D, and parathyroid 
hormone (PTH)) of the control group were retrieved 
from the laboratory database and matched with the 
cases. 
These control individuals were healthy persons 
without any serious medical disorders that referred to the 
laboratory from December 1 to January 20, 2019 prior 
to the pandemic of COVID-19 by their primary care 
physicians for the routine checkup. We did not select 
control individuals from the hospitalized patients during 
the pandemic to avoid any risk of false negative or false 
positive results for the COVID-19 infection.  
Data Collection  
Data including age, sex, initial symptoms and 
duration of hospitalization was collected from the 
electronic medical records. The serum levels of calcium, 
aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), 
albumin, blood urea nitrogen (BUN), creatinine, 
sodium, potassium, white blood cell (WBC) count, 
lymphocyte count, hemoglobin, vitamin D, PTH and O2 
saturation were recorded within 24 hours of admission.  
Ethical Considerations 
Although most information was extracted from data 
available on clinical records of individuals, data on some 
laboratory tests (e.g., parathyroid hormone, vitamin D) 
were required for the research purposes while these tests 
had not been performed for the clinical purposes. These 
tests were performed by the use of serum samples of the 
patients which routinely stored and then left over after 
diagnostic procedures. Consequently, it was not required 
to repeat venipuncture and blood collection, thus, 
patients were not bothered to take additional risk or harm 
for the research purposes. Therefore, the implicit consent 
was obtained from the patients during their clinical 
workups. Furthermore, to protect the confidentiality and 
privacy of individuals, strategies such as coding were 
employed during data registry and analysis. 
Statistical Analysis 
The data were summarized as frequencies and 
percentages for the categorical variables and Means ± 
SD for the continuous ones. Differences between 
variables among groups were analyzed using 
independent sample T-test and Chi-square test where 
appropriate. Logistic regression was used to calculate 
odds ratios (OR) with 95% confidence intervals for the 
categorical outcomes. The analysis was performed by 
SPSS version 23 and STATA version 0.05 and statistical 
significance was defined as P-value<0.05.STATA 
version 0.05 was used to create the Figures. 
 
Results 
All 91 PCR-confirmed COVID-19 patients and 169 
controls enrolled in the study were older than 18. The 
age ranged from 18 to 90 years old. Cough and dyspnea 
were prominent in 83.3% and 73.8% of patients, 
respectively which were recorded as the main initial 
symptoms. Duration of hospitalization was from 1 to 15 
days with a mean of 7.32 ± 3.03 days. The rate of ICU 
admission was 24.4%. Fourteen patients with severe 
COVID-19 infection (16.3%) were expired. Other 
characteristics of the patients are shown in Table 1. The 
range, mean ± SD, and the percentage of abnormal 
values for some admission laboratory findings of 91 
COVID-19 patients are shown in Table 2. 
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  Table 1. Clinical Characteristics of 91 Patients with COVID-19. 
Parameter Mean ± SD/ % Range Abnormal (%) 
Pre-admission signs and symptoms 
Respiratory rate 21.76± 6 14-57 43.5%>20 
Heart rate 86.17±19.2 37-148 7.5%<60 &11.2% >100 
Diastolic blood pressure 74.21 ± 9.3 50-90 3.9%<60 
Systolic blood pressure 117.57 ± 14.2 70-150 1.3%<90 & 2.3%>140 
Oral temperature 37.92 ± 0.7 36-39.7 81.6 >37.3 
O2 saturation 86.06 ± 11 11.24 40-97 50 
Cough 83.3%  
Dyspnea 73.8%  
Pre-admission co-morbidities 
Hypertension 27.2  
Diabetes mellitus 16.2  
Ischemic Heart Disease 12.5  
Hyperlipidemia 11.4  
COPD * 8.6  
Hypothyroidism 4.9  
Asthma 2.4  
Chronic kidney disease 0  
Chronic liver disease 0  
Outcome 
Duration of hospitalization 7.46 ± 3.03 1-15  
ICU admission 24.1  
Death 16.3  
    
 
* Chronic Obstructive Pulmonary Disease 
 
Table 2. Admission Laboratory Findings of 91 COVID-19 Patients 
Parameter Mean ± SD/ % Range Abnormal (%) 
Pre-admission signs and symptoms 
Respiratory rate 21.76± 6 14-57 43.5%>20 
Heart rate 86.17±19.2 37-148 7.5%<60 &11.2% >100 
Diastolic blood pressure 74.21 ± 9.3 50-90 3.9%<60 
Systolic blood pressure 117.57 ± 14.2 70-150 1.3%<90 & 2.3%>140 
Oral temperature 37.92 ± 0.7 36-39.7 81.6 >37.3 
O2 saturation 86.06 ± 11 11.24 40-97 50 
Cough 83.3%  
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Parameter Mean ± SD/ % Range Abnormal (%) 
Dyspnea 73.8%  
Pre-admission comorbidities 
Hypertension 27.2  
Diabetes mellitus 16.2  
Ischemic Heart Disease 12.5  
Hyperlipidemia 11.4  
COPD * 8.6  
Hypothyroidism 4.9  
Asthma 2.4  
Chronic kidney disease 0  
Chronic liver disease 0  
Outcome 
Duration of hospitalization 7.46 ± 3.03 1-15  
ICU admission 24.1  
Death 16.3  
    
 
*Statistical Significance at P-value<0.05 
 
Comparing the cases with the controls, there was a 
significant difference in the number of patients with 
hypocalcemia (corrected serum calcium <8.6). The 
percentages of hypocalcemia were 59.3% and 32.5% in 
the cases and control groups, respectively (OR=3.02, 
95% CI: 1.79-5.13, P<0.001). Moreover, the mean 
serum calcium level of COVID-19 patients at the time 
of admission was significantly less than this level in 
control group (8.36 ± 0.57 vs 8.79 ± 0.35 mg/dL, P< 
0.001). However, differences in the vitamin D and PTH 
levels did not reach the statistical significance. Also, 
there were significant differences in the mean levels of 
other laboratory findings in the patients affected by 
COVID-19 compared to the healthy controls which are 
presented in Table 3. .
 
Table 3. Admission Laboratory Findings of COVID-19 Patients in Comparison with Those of Controls 
 COVID-19 (n=91) Controls (n=169) P-value 
Variable Mean ± SD or % Mean ± SD or %  
Sex (male) 60.4% 66.9% 0.34 
Age 55.44 ± 16.9 55.91 ± 15.2 0.82 
Calcium (mg/dL) † 8.36 ± 0.57 8.79 ± 0.35 < 0.001* 
Hypocalcemia†† ^ 59.3% 32.5% <0.001* 
Vitamin D (nmol/L) 73.16 ± 23.59 76.02 ± 23.48 0.37 
PTH (pg/mL) 45.13 ± 23.2 46.25 ± 10.82 0.545 
White Blood Cell (×10 9/μL) 7.330 ± 4.5441 6.636 ± 1.83 0.16 
Lymphocyte (×10 9/μL) 1.163 ± 5.88 3.49 ± 0.89 < 0.001* 
Hemoglobin (g/dL) 14.0 ± 2 14.5 ± 1.9 0.05* 
Albumin (g/dL) 3.73 ± 0.49 4.52 ± 0.2 < 0.001* 
BUN (mg/dL) 16.45 ± 10.33 16.45 ± 4.7 0.176 
Creatinine (mg/dL) 0.84 ± 0.27 0.92 ± 0.16 0.002* 
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 COVID-19 (n=91) Controls (n=169) P-value 
Sodium (mmol/L) 136.97 ± 3.34 141.6 ± 1.3 < 0.001* 
Potassium (mmol/L) 4.08 ± 0.37 4.46 ± 0.57 < 0.001* 
ALT (U/L) 32.32 ± 41.92 24.3 ± 12.36 0.084 
AST (U/L) 33.93 ± 53.92 18.44 ± 6.1 0.008* 
ALK (U/L) 153.46±39.01 201.98 ± 42.23 < 0.001* 
 
* Statistical Significance at P-value<0.05 
† Calcium levels were corrected by albumin (corrected calcium=calcium + (0.8 × (4-albumin))) 
†† Hypocalcemia means serum calcium level ≤8.6 mg/dL 
^ OR=3.02, 95% CI: 1.79-5.13 
 
In evaluation among the COVID-19 patients, the 
association between serum calcium level and their 
clinical outcome was investigated by two types of 
analysis:  calcium level measurement and degree of 
severity of the disease. 
Firstly, patients were divided into two groups (as 
shown in Table 4) based on their serum calcium values. 
The rates of death and ICU admission were 
significantly higher among the patients in 
hypocalcemic group than those of eucalcemic group 
(85.7% vs 14.3% and 33.3% Vs 9.1%, respectively). 
However, there was no significant difference in the 
mean PTH and vitamin D levels between the two 
groups. In terms of the severity of the infection, 74.1% 
of patients in hypocalcemic group had a severe 
infection while 24.3% in eucalcemic group were 
diagnosed with severe infection (OR=8.89, 95% CI: 
3.38-23.37, P<0.001). The rate of hypocalcemia was 
not significantly different between male and female 
patients (65% vs 77%, respectively; P=0.34).
 
 
Table 4. Comparison of clinical and laboratory findings in 91 COVID-19 patients in regard to the calcium level 
Variable 
Hypocalcemic patients † 
(n=54) 
Eucalcemic patients †† 
(n=37) 
P-value 
 Mean ± SD / Percentage Mean ± SD / Percentage  
Sex (male) 60 % 40 % 0.52 
Age (year) 55.67 ± 15.9 55.11 ± 18.4 0.88 
Hospitalization (day) 7.96 ± 3.1 6.66 ± 2.8 0.17 
ICU admission 33.3% 9.1% 0.008* 
Death 22.06% 6.1% 0.04* 
Severity 81.6% 18.4% <0.001* 
Dyspnea 61.3% 38.7% 0.37 
O2 saturation 84.26 ± 12.35 89.07 ± 7.57 0.05* 
WBC (×109/μL) 7.94 ± 5.24 6.43 ± 3.11 0.9 
Lymphocyte (×109/μL) 1.09 ± 0.56 
1.25 ± 0.61 
0.5 
0.2 
Hemoglobin (g/dL) male 14.9 ± 1.5 14.7 ±1.75 0.65 
Hemoglobin (g/dL) female 12.79 ± 2.1 12.68 ± 1.35 0.86 
Albumin (g/dL) 3.75 ± 0.54 
3.7 ± 0.42 
0.3 
0.68 
Vitamin D (nmol/L) 73.89 ± 20.38 72.1 ± 19.22 0.73 
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Variable 
Hypocalcemic patients † 
(n=54) 
Eucalcemic patients †† 
(n=37) 
P-value 
PTH (pg/mL) 46.79 ± 26.75 42.57 ±16.46 0.41 
† Serum calcium level ≤8.6 mg/dL 
†† Serum calcium level >8.6 mg/dL and ≤ 10.5 
* Statistical significance at P< 0.05 
 
 
Secondly, patients were divided into categories of 
severity based on the above-mentioned criteria. While 
there was no patient with mild infection, 53.8% were 
classified as severe and the rest as moderate infection. 
Table 5 compares the clinical and laboratory findings 
between the patients with moderate and severeCOVID-
19 infection. The rate of severe disease in male patients 
was not significantly different from the females (55.5% 
vs 52.7%, respectively; P=0.83) 
The serum calcium levels showed significant 
positive and negative correlations with O2 saturation 
and respiratory rates, respectively. These results were 
independent of the vitamin D and PTH levels in 
COVID-19 patients (as the levels were not 
significantly different between the cases and controls 
as well as patients with moderate and severe diseases). 
Regarding the age factor, the mean age of cases and 
controls were 55.44±16.9 and 55.91±15.2, 
respectively; as the controls were matched according to 
the age, as expected, no significant difference was 
found (P=0.82, as shown in Table 3). Also, the mean 
age of hypocalcemic and eucalcemic patients was not 
significantly different (55.67 vs 55.11, respectively, 
P=0.87). Furthermore, the level of calcium was not 
correlated with the age factor (Pearson=-0.08 and 
P=0.44). 
Regarding sex, 60.4% cases and 66.9% controls 
were male; as the controls were matched according to 
the sex, as expected, no significant difference was 
found (P=0.34, as shown in Table 3). Among the 
COVID-19patients, 54. 2% of males and 52.8% of 
females had severe diseases (P=0.5). Additionally, the 
rate of death as final outcome in the female patients 
was higher, but the difference was not statistically 
significant (24.2% vs 11.3%, respectively and P=0.14). 
And finally, the mean of calcium level in male and 
female patients was not significantly different (8.34 vs 
8.38, respectively and P=0.79). 
The ROCs were also calculated to assess the 
associations between serum calcium level and severity 
of the infection as well as mortality (Figures 1 and 2). 
The optimal cut-off points of serum calcium values 
were derived from the ROCs. The optimal cut-off point 
for the severity was 8.69 mg/dL, (sensitivity 91.8%, 
and specificity 63.4%). The optimal cut-off point for 
mortality was 8.38 mg/dL, (sensitivity 71.4%, and 
specificity 57.7%).
 
Table 5. Comparison of clinical and laboratory findings in 91 COVID-19 patients in regard to the clinical severity 
 Moderate (n=42) Severe (n=49) P-value 
Variable Mean ± SD / N (%) Mean ± SD / N (%)  
Sex (male) 59.5 61. 2 0.51 
Age (year) 49.6 ± 15.4 60.39 ± 16.7 0.02* 
Hospitalization(day) 6.66 ± 2.8 7.96 ± 3.09 0.05 
ICU admission 0 42.9 <0.001 
Death 0 29.2 <0.001 
Respiratory rate 20 ± 4.03 22.82 ± 6.66 0.03 
O2 saturation 89.07 ± 5.02 84.26 ± 12.35 <0.001* 
WBC(×109/μL) 6.74 ± 3.48 7.83 ± 5.26 0.25 
Lymphocyte(×109/μL) 1.32 ± 0.55 1.02 ± 0.58 0.01* 
Hemoglobin(g/dL) male 15 ± 1.6 14.6 ± 1.5 0.31 
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 Moderate (n=42) Severe (n=49) P-value 
Variable Mean ± SD / N (%) Mean ± SD / N (%)  
Hemoglobin(g/dL) female 12.7±1.2 12.7±2.2 0.8 
Albumin(g/dL) 3.88 ± 0.47 3.60 ± 0.48 0.007* 
BUN(mg/dL) 14 ± 6.89 18.55 ± 12.24 0.029 
Creatinine(mg/dL) male 0.82 ± 0.15 1 ± 0.43 0.05 
Creatinine(mg/dL) female 0.71 ±0.12 0.94±0.53 0.08 
Sodium(mmol/L) 137.5 ± 2.8 136.4 ± 3.6 0.11 
Potassium(mmol/L) 4.11± 0.38 4.05 ± 0.37 0.42 
Vitamin D(nmol/L) 70.7 ± 19.2 75.2 ± 26.8 0.40 
PTH(pg/mL) 43.08 ± 17.2 ± 16.44 
47.0 ± 27.68 
± 28.01 0.47 
Calcium (mg/dL) 8.69 ± 0.41 8.08 ± 0.54 < 0.001* 





Fig. 1. ROC curves showing the association between serum calcium level and severity of disease. The optimal 
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Fig. 2. ROC curves showing the association between the serum calcium level and mortality. The optimal cut-
off point for the mortality was 8.38 mg/dL; sensitivity 71.4%, and specificity 57.7%). 
 
Discussion  
This study demonstrated the association between 
total serum calcium level and the severity of the 
infection as well as the major outcome in the patients 
with COVID-19 infection. This is one of the first 
studies that addressed this issue in COVID-19 patients 
and healthy control group. Although nowadays there 
are suggestive methods for the diagnosis and treatment 
of COVID-19 disease, the mortality rate of critical 
patients with severe disease is still high which is 
important to identify the risk factors for the severe 
illness or death (10). However, few reports have been 
published to establish an early and sensitive biomarker 
to predict the severity of the disease and prognosis of 
COVID-19, especially in Iran. In this study, we found 
that serum calcium level would be associated with the 
severity of the disease and prognosis of the patients 
with COVID-19. 
Mild hypocalcemia has already been shown to be 
common in the patients with SARS and Ebola 
infections (11,12). Since the beginning of the 
pandemic, a few studies have addressed hypocalcemia 
as an important laboratory finding in COVID-19 
patients (13-15). The prevalence of hypocalcemia was 
59.3% in our patients. This result was in line with the 
previous published studies. In the studies conducted by 
Sun et al., and Cao et al., 74.7% and 65.4% of the 
COVID-19 patients, respectively had hypocalcemia 
(13, 14).  
One of our key findings was that patients with 
lower level of serum calcium (especially ≤ 8.6mg/dL) 
exhibited a more severe form of COVID-19 infection 
and a higher rate of ICU admission and mortality. 
These findings are consistent with the results of the 
study by Sun et al. (13). 
Comparing COVID-19 patients regarding sex and 
age and the correlation between these factors and 
calcium levels or clinical outcome showed that age and 
sex were not confounding variables. 
Calcium homeostasis is regulated by the vitamin D 
and the PTH-calcium axis. Dysfunction of PTH is 
highly prevalent in the critical illnesses (16), and 
hypocalcemia is common in critically ill patients (17). 
Moreover, hypocalcemia is associated with the organ 
dysfunction and poor outcomes in critically ill patients 
(18). Interestingly, hypocalcemia in our patients was 
independent of vitamin D and PTH levels, and these 
measures were not significantly different between our 
cases and controls. However, Sun et al., revealed that 
hypocalcemia was associated with hypoproteinemia, 
imbalanced vitamin D and PTH levels in the acute 
phase of COVID-19 infection (13). Hence, our 
observation provides a new insight into the correlation 
between hypocalcemia and COVID-19 infection. It is 
essential to identify the mechanism of action of the 
virus, as well as the risk factors that lead to more severe 
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of the multi-organ dysfunction due to COVID-19 
infection is still unknown. It is also unknown if there is 
a higher risk of hypocalcemia associated with COVID-
19 or if COVID-19 infection causes hypocalcemia. 
Several studies have indicated that the concentration of 
inflammatory markers including the cytokines is higher 
in the serum of the COVID-19 patients than in healthy 
adults (20, 21). Pro-inflammatory cytokines such as 
interleukin-1 (IL-1) and interleukin-6 (IL-6) are 
important mediators of the acute response to the critical 
illness. The association between hypocalcemia and 
more severe infection in our study can be justified by 
the interplay between serum calcium level and the 
immune system that has been proposed by others (22-
25). The findings of this study which were consistent 
with the previous reports, confirmed that serum 
calcium level would be associated with the severity of 
the disease and prognosis of the patients with COVID-
19. 
Additionally, our study revealed that patients with 
COVID-19 infection had lower sodium and potassium 
level compared to the control group and appropriate 
management of these imbalances will be useful in the 
treatment of COVID-19 patients. Li et al., showed that 
hypokalemia is known to exacerbate acute respiratory 
distress syndrome (ARDS) and acute cardiac injury, 
which are considered as   common complications in 
COVID-19 patients (26). 
This study faced some limitations that need to be 
discussed. We had a small sample size that could affect 
the results, but most of the results were in line with the 
previous studies that indicates the reliability of our 
study. We also measured the total calcium serum level 
rather than ionized calcium, which may not precisely 
reflect the exact total level of the calcium. 
 
Conclusion  
This study highlighted the high incidence of 
hypocalcemia in the patients with severe COVID-19 
infection. Patients with lower total serum calcium 
levels (especially ≤ 8.45 mg/dL) had worse clinical 
outcome, and higher mortality rate. The serum calcium 
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